Grufity logoGrufity logo

Evolent Health Inc Stock Research

EVH

31.73USD+1.44(+4.75%)Market Closed

Market Summary

USD31.73+1.44
Market Closed
4.75%

EVH Alerts

EVH Stock Price

EVH RSI Chart

EVH Valuation

Market Cap

3.0B

Price/Earnings (Trailing)

-157.77

Price/Sales (Trailing)

2.24

EV/EBITDA

137.03

Price/Free Cashflow

-261.7

EVH Price/Sales (Trailing)

EVH Profitability

EBT Margin

-4.59%

Return on Equity

-2.23%

Return on Assets

-1.05%

Free Cashflow Yield

-0.38%

EVH Fundamentals

EVH Revenue

Revenue (TTM)

1.4B

Revenue Y/Y

53.98%

Revenue Q/Q

8.47%

EVH Earnings

Earnings (TTM)

-19.2M

Earnings Y/Y

-100.97%

Earnings Q/Q

-634.57%

Price Action

52 Week Range

21.8339.78
(Low)(High)

Last 7 days

-11.7%

Last 30 days

-7.0%

Last 90 days

9.3%

Trailing 12 Months

4.6%

EVH Financial Health

Current Ratio

1.1

EVH Investor Care

Shares Dilution (1Y)

11.06%

Diluted EPS (TTM)

-0.2

Peers (Alternatives to Evolent Health)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
440.9B
324.2B
-6.04% -5.61%
21.91
1.36
12.71% 16.40%
98.6B
322.5B
-16.10% -28.31%
23.76
0.31
10.39% -47.55%
27.9B
-
0.98% 20.75%
47.36
4.81
- -
27.3B
2.1B
-0.47% -1.83%
68.93
13.15
17.88% -8.53%
MID-CAP
9.0B
3.5B
11.88% 31.28%
-116.8
2.57
7.15% -34.72%
6.5B
-
-7.53% -10.06%
64.74
4.3
- -
4.1B
2.4B
-16.92% -54.15%
-0.3
1.71
18.41% -3085.58%
3.8B
1.4B
-2.87% -11.96%
21.41
2.78
-19.68% -41.10%
3.0B
1.4B
-7.00% 4.56%
-157.77
2.24
48.91% 49.03%
SMALL-CAP
1.8B
262.3M
-10.85% 40.30%
-9.92
6.98
33.16% -131.28%
1.1B
625.9M
-11.35% -14.10%
49.5
1.81
6.21% 3223.77%
864.4M
53.5M
4.26% 2.91%
80.77
16.17
10.94% 3.61%
657.1M
276.2M
-14.12% -43.94%
-4.78
2.38
14.18% 10.32%
234.3M
63.1M
-26.73% -64.73%
-22.34
3.71
9.93% -1043.45%
155.2M
357.1M
-7.94% 20.85%
-1.11
0.43
33.22% -57.66%

Financials for Evolent Health

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue11.0%1,3521,2181,088990908
Operating Expenses7.2%1,019950---
  S&GA Expenses6.3%269253236220219
  R&D Expenses-16.00----
EBITDA-28.2%21.0029.0059.0058.00-
EBITDA Margin-35.3%0.02*0.02*0.05*0.06*-
Earnings Before Taxes-26.0%-62.08-49.25-18.66-23.37-29.80
EBT Margin-13.5%-0.05*-0.04*-0.02*-0.02*-
Interest Expenses-0.1%16.0016.0017.0021.0025.00
Net Income-42.4%-19.16-13.46-28.62-33.14-37.60
Net Income Margin-28.2%-0.01*-0.01*-0.03*-0.03*-
Free Cahsflow-159.5%-11.5519.0067.0029.00-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets3.3%1,8171,7591,3041,3391,419
  Current Assets21.4%478394423463524
    Cash Equivalents20.1%188157193210266
  Net PPE-7.2%88.0095.0093.0083.0081.00
  Goodwill0.0%723723426426426
Liabilities6.1%958903691728726
  Current Liabilities13.5%433382343382445
    LT Debt, Current------
    LT Debt, Non Current0.1%413412283283216
Shareholder's Equity0.4%859856613611694
  Retained Earnings-1.9%-606-594-596-592-626
  Additional Paid-In Capital1.0%1,4871,4721,2311,2241,341
Shares Outstanding5.8%95.0090.0090.00--
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-159.5%-11.5519.0067.0029.0039.00
  Share Based Compensation39.8%34.0024.0022.0018.0017.00
Cashflow From Investing16.2%-259-309-55.84-44.97-15.79
Cashflow From Financing-35.3%13220331.00-25.34-29.55

Risks for EVH

What is the probability of a big loss on EVH?

95.8%


Probability that Evolent Health stock will be more than 20% underwater in next one year

83.5%


Probability that Evolent Health stock will be more than 30% underwater in next one year.

47.7%


Probability that Evolent Health stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does EVH drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Evolent Health was unfortunately bought at previous high price.

Drawdowns

Returns for EVH

Cumulative Returns on EVH

17.3%


7-Year Cumulative Returns

15.7%


5-Year Cumulative Returns

76.8%


3-Year Cumulative Returns

What are the long-term rolling returns for EVH?

FIve years rolling returns for Evolent Health.

Annualized Returns

Which funds bought or sold EVH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
23.55
-1,270,850
35,661,200
0.04%
2023-03-06
Rockefeller Capital Management L.P.
unchanged
-
-1,000
3,000
-%
2023-02-28
Voya Investment Management LLC
added
110
6,016,230
15,390,200
0.02%
2023-02-24
NATIXIS
new
-
634,917
634,917
-%
2023-02-21
MACQUARIE GROUP LTD
reduced
-23.91
-21,241,000
31,080,000
0.04%
2023-02-17
Ascent Group, LLC
reduced
-1.31
-62,396
422,604
0.05%
2023-02-17
TRUIST FINANCIAL CORP
reduced
-1.53
-922,698
3,081,300
-%
2023-02-16
IMA Wealth, Inc.
reduced
-5.91
-833,152
2,313,850
0.61%
2023-02-16
HARBOUR INVESTMENTS, INC.
reduced
-5.59
-61,485
388,515
0.02%
2023-02-15
GABELLI & Co INVESTMENT ADVISERS, INC.
unchanged
-
-62,360
224,640
0.05%

1–10 of 38

Latest Funds Activity

Are funds buying EVH calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own EVH
No. of Funds

Evolent Health News

MarketBeat

Evolent Health, Inc. (NYSE:EVH) Receives Consensus Rating of ....

MarketBeat,
5 hours ago

DirectorsTalk Interviews

InvestorsObserver

The Motley Fool

Zacks Investment Research

Simply Wall St

Schedule 13G FIlings of Evolent Health

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 08, 2023
upmc
1.97%
2,190,702
SC 13G/A
Feb 14, 2023
granahan investment management, llc
3.12%
3,155,211
SC 13G/A
Feb 09, 2023
vanguard group inc
9.68%
9,790,816
SC 13G/A
Feb 03, 2023
upmc
5.84%
5,907,841
SC 13G/A
Jan 31, 2023
blackrock inc.
7.6%
7,701,919
SC 13G/A
Jan 27, 2023
magellan health inc
8.4%
8,474,576
SC 13G
Jan 20, 2023
jpmorgan chase & co
5.3%
5,368,825
SC 13G/A
Aug 25, 2022
engaged capital llc
2.8%
2,585,187
SC 13D/A
Jul 11, 2022
engaged capital llc
3.2%
2,936,627
SC 13D/A
May 09, 2022
engaged capital llc
4.4%
3,989,962
SC 13D/A

EVH Fair Value

Evolent Health fair value in different scenarios

The table shows the Fair Value estimates for Evolent Health for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

19.97

-37.06%

29.82

-6.02%

50.36

58.71%

82.44

159.82%

138.30

335.87%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Evolent Health Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Evolent Health

View All Filings
Date Filed Form Type Document
Mar 08, 2023
SC 13G/A
Major Ownership Report
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading

Latest Insider Trading transactions for EVH

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-07
Blackley Seth
sold
-3,290,800
34.62
-95,055
chief executive officer
2023-03-07
WILLIAMS FRANK J
sold
-4,026,690
34.62
-116,311
-
2023-03-06
WILLIAMS FRANK J
sold
-3,109,740
34.4166
-90,356
-
2023-03-06
Blackley Seth
sold
-2,544,350
34.4166
-73,928
chief executive officer
2023-03-03
WILLIAMS FRANK J
acquired
-
-
400,000
-
2023-03-03
Blackley Seth
acquired
-
-
360,000
chief executive officer
2023-03-02
Weinberg Jonathan
sold (taxes)
-117,050
35.15
-3,330
general counsel
2023-03-02
Tutewohl Steve
sold (taxes)
-112,480
35.15
-3,200
chief operating officer
2023-03-02
Johnson John Paul
sold (taxes)
-317,053
35.15
-9,020
chief financial officer
2023-03-02
McCarthy Daniel Joseph
sold (taxes)
-164,748
35.15
-4,687
president

1–10 of 50

About Evolent Health

EVH Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands
3 Months Ended12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]    
Revenue[1] $ 1,352,013,000$ 907,957,000$ 924,639,000
Expenses    
Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)[1] 1,035,429,000657,551,000696,581,000
Selling, general and administrative expenses[1] 269,269,000219,499,000210,412,000
Depreciation and amortization expenses 67,195,00060,037,00060,835,000
Loss on disposal of assets and consolidation 00698,000
Goodwill impairment 00215,100,000
Change in fair value of contingent consideration (23,522,000)13,281,0003,860,000
Total operating expenses$ 384,310,0001,348,371,000950,368,0001,187,486,000
Operating income (loss) 3,642,000(42,411,000)(262,847,000)
Interest income 1,369,000407,0002,633,000
Interest expense (15,572,000)(25,425,000)(28,325,000)
Impairment of equity method investments 0047,133,000
Gain from equity method investees 4,569,00013,179,00010,039,000
Gain on transfer of membership 045,938,0000
Loss on extinguishment/repayment of debt (10,192,000)(21,343,000)(4,789,000)
Change in tax receivable agreement liability (45,950,000)00
Other income (expense), net 57,000(146,000)(118,000)
Loss from continuing operations before income taxes (62,077,000)(29,801,000)(330,540,000)
Provision for (benefit from) income taxes (43,376,000)483,000(2,368,000)
Loss from continuing operations (18,701,000)(30,284,000)(328,172,000)
Loss from discontinued operations, net of tax[2] (463,000)(7,317,000)(6,074,000)
Net loss attributable to common shareholders of Evolent Health, Inc - Basic(11,349,000)(19,164,000)(37,601,000)(334,246,000)
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted$ (11,349,000)$ (19,164,000)$ (37,601,000)$ (334,246,000)
Basic and diluted:    
Continuing operations (in dollars per share)$ (0.11)$ (0.20)$ (0.35)$ (3.86)
Continuing operations (in dollars per share)(0.11)(0.20)(0.35)(3.86)
Discontinued operations (in dollars per share)00(0.09)(0.08)
Discontinued operations (in dollars per share)$ 00(0.09)(0.08)
Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share) (0.20)(0.44)(3.94)
Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share) $ (0.20)$ (0.44)$ (3.94)
Weighted-average common shares outstanding    
Basic (in shares) 93,69986,06784,928
Diluted (in shares) 93,69986,06784,928
Comprehensive loss    
Net loss $ (19,164,000)$ (37,601,000)$ (334,246,000)
Other comprehensive loss, net of taxes, related to:    
Foreign currency translation adjustment (816,000)(84,000)(44,000)
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. $ (19,980,000)$ (37,685,000)$ (334,290,000)
[1]See Note 19 for amounts attributable to unconsolidated related parties included in these line items.
[2]Includes $0.5 million and $6.8 million of loss on disposal of discontinued operations for years ended December 31, 2022 and 2021, respectively

EVH Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 188,200$ 266,280
Restricted cash and restricted investments14,49275,685
Accounts receivable, net[1]254,684130,604
Prepaid expenses and other current assets[1]20,67851,391
Total current assets478,054523,960
Restricted cash and restricted investments12,46612,977
Investments in equity method investees4,4755,458
Property and equipment, net87,87481,365
Right-of-use assets - operating49,02750,203
Prepaid expenses and other noncurrent assets[1]2,3786,790
Contract cost assets17,46132,624
Intangible assets, net442,784279,784
Goodwill722,774426,297
Total assets1,817,2931,419,458
Current liabilities:  
Accounts payable[1]57,17496,084
Accrued liabilities[1]111,198107,241
Operating lease liability - current7,1227,069
Accrued compensation and employee benefits52,46051,861
Deferred revenue5,75811,944
Reserve for claims and performance-based arrangements[1]199,730171,294
Total current liabilities433,442445,493
Long-term debt, net412,986215,676
Other long-term liabilities4,7445,531
Tax receivable agreement liability45,9500
Operating lease liabilities - noncurrent56,01057,722
Deferred tax liabilities, net4,7441,403
Total liabilities957,876725,825
Commitments and Contingencies (See Note $11)
Shareholders' Equity  
Class A common stock - $0.01 par value; 750,000,000 shares authorized; 101,500,558 and 90,758,318 shares issued, respectively1,015908
Additional paid-in-capital1,486,8571,340,989
Accumulated other comprehensive loss(1,178)(362)
Retained earnings (accumulated deficit)(606,154)(626,779)
Treasury stock, at cost; 1,537,582 shares issued, respectively(21,123)(21,123)
Total shareholders' equity859,417693,633
Total liabilities and shareholders' equity$ 1,817,293$ 1,419,458
[1]See Note 19 for amounts attributable to related parties included in these line items.